US Drug Companies Eye Gabonese Root for Addiction Treatment

US pharmaceutical companies are increasingly interested in ibogaine, a compound derived from the root bark of the iboga shrub native to Gabon, for potential treatments for addiction and mental health conditions. This surge in interest has drawn comparisons to the global rise of ayahuasca and has prompted concerns in Gabon about overharvesting and the potential disappearance of the plant.

For generations, the iboga root has been a central element in the sacred Bwiti spiritual ceremonies of Gabon. Participants consume the bitter root bark during all-night rituals, believing it helps them confront trauma, gain insight, and overcome personal struggles. Traditionally harvested from surrounding forests, the plant is consumed by chewing or swallowing shavings, inducing a dream-like state lasting over 24 hours, often accompanied by vivid memories and introspection.

However, accessing iboga is becoming more difficult, according to Yann Guignon, president of the conservation organization Blessings of the Forest. He estimates that 85 to 90 percent of wild iboga has disappeared due to poaching over the past 50 years. Guignon warned of significant trafficking to the West, where the plant commands higher prices, impacting traditional practitioners and raising fears that the species could be depleted.

Several US pharmaceutical firms are investigating ibogaine and related compounds as potential therapies. Early research suggests ibogaine may help reduce cravings for drugs and alcohol, ease withdrawal symptoms, and potentially treat depression, anxiety, and post-traumatic stress disorder. A 2024 study from Stanford Medicine indicated that veterans with traumatic brain injuries experienced significant reductions in PTSD, depression, and anxiety symptoms after ibogaine treatment, though larger controlled trials are still needed.

The growing attention has also attracted celebrity endorsements. Former boxing champion Mike Tyson has spoken positively about his experiences with ibogaine, describing it as life-changing, while former stockbroker Jordan Belfort has discussed seeking ibogaine treatment for prescription medication withdrawal.

Despite its potential, researchers caution that ibogaine carries risks, including dangerous heart rhythm disturbances in some individuals. The substance remains illegal or tightly regulated in many countries. Gabon is currently exploring measures to protect both the iboga species and its associated traditions, with advocates arguing that any medical benefits derived from iboga should ultimately serve the communities that have long utilized the plant.